Breaking News Instant updates and real-time market news.

JNJ

Johnson & Johnson

$136.52

2.62 (1.96%)

, V

Visa

$108.42

1.11 (1.03%)

10:24
10/11/17
10/11
10:24
10/11/17
10:24

On The Fly: Top five analyst upgrades

Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Johnson & Johnson (JNJ) upgraded to Buy from Hold at Jefferies with analyst Jeffrey Holford saying J&J's Pharma division is "under-modeled" by analysts and will drive above-consensus revenue and earnings growth. 2. Visa (V) and MasterCard (MA) were upgraded to Outperform from Market Perform at Wells Fargo. 3. Colgate-Palmolive (CL) upgraded to Buy from Hold at SunTrust with analyst William Chappell saying the recent three consecutive quarters of weak results is an "anomaly" given the company's long term track record of consistent mid-single-digit or higher organic growth. 4. AbbVie (ABBV) upgraded to Outperform from Market Perform at Cowen with analyst Steve Scala saying AbbVie "showed the best" of all the companies at Cowen's Annual Therapeutics Conference last week. 5. PayPal (PYPL) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst James Faucette calling it among the few large companies that can deliver high-teens revenue and 20% EPS growth. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

JNJ

Johnson & Johnson

$136.52

2.62 (1.96%)

V

Visa

$108.42

1.11 (1.03%)

MA

MasterCard

$146.42

0.77 (0.53%)

CL

Colgate-Palmolive

$74.68

1.78 (2.44%)

ABBV

AbbVie

$91.91

0.74 (0.81%)

PYPL

PayPal

$66.04

-0.19 (-0.29%)

  • 11

    Oct

  • 11

    Oct

  • 11

    Oct

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 18

    Oct

  • 19

    Oct

  • 22

    Oct

  • 23

    Oct

  • 25

    Oct

  • 27

    Oct

  • 27

    Oct

  • 31

    Oct

  • 06

    Nov

  • 08

    Nov

  • 29

    Nov

JNJ Johnson & Johnson
$136.52

2.62 (1.96%)

10/11/17
JEFF
10/11/17
UPGRADE
Target $157
JEFF
Buy
Johnson & Johnson upgraded to Buy from Hold at Jefferies
Jefferies analyst Jeffrey Holford upgraded Johnson & Johnson to Buy while raising his price target for the shares to $157 from $145. The healthcare giant closed yesterday up 36c to $133.90. J&J's Pharma division is "under-modelled" by analysts and will drive above-consensus revenue and earnings growth, Holford tells investors in a research note. He sees the company's TIRADE pharma assets, or Tremfya, Imbruvica, rivaroxaban, Apalutamide, Darzalex, Esketamine and Stelara, as well as synergies from the Actelion acquisition, driving strong earnings momentum and better than expected dividends. Holford expects J&J shares to re-rate to a 10% market premium.
10/09/17
10/09/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Johnson & Johnson (JNJ) upgraded to Outperform from Market Perform at Wells Fargo with analyst Larry Biegelsen saying J&J is poised to reaccelerate its sales growth due to accretion from the Actelion acquisition, a "more measured" than expected impact from biosimilar competition, "solid performance" of key drugs and a pipeline that is "coming to fruition." 2. Morgan Stanley (MS) upgraded to Outperform from Neutral at Credit Suisse with analyst Susan Roth Katzke citing the over 10% total return potential in the shares. 3. Disney (DIS) upgraded to Top Pick from Outperform at RBC Capital with analyst Steven Cahall saying he thinks the company has reached a turning point with ESPN approaching less than 20% of earnings and "non-Media" Disney remaining a global leader in content that is executing well. 4. INC Research (INCR) upgraded to Buy from Hold at Jefferies analyst David Windley saying the recent share pullback provides a "compelling" entry point. 5. British American Tobacco (BTI) upgraded to Buy from Neutral at Goldman Sachs. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/09/17
10/09/17
NO CHANGE

Valuations in Medical Technology look more attractive, says RBC Capital
RBC Capital analyst Glenn Novarro says the recent pullback in Medical Technology stocks since Q2 earnings has eliminated the valuation gap relative to other S&P Health Care subsectors. The analyst recommends a "Buy Now" for Johnson & Johnson (JNJ) and "Buy on Weakness" for Abbott Laboratories (ABT) among diversified MedTech names. In Cardiovascular, Novarro says "Buy Now" for Edwards Lifesciences (EW) and "Buy on Weakness" for Boston Scientific (BSX). For Nuvasive (NUVA) and Wright Medical (WMGI), the analyst says management will cut guidance because of hurricane related revenue shortfalls, but the selloff over the past several weeks is already discounting those expectations.
10/09/17
WELS
10/09/17
UPGRADE
Target $149
WELS
Outperform
Johnson & Johnson upgraded to Outperform from Market Perform at Wells Fargo
Wells Fargo analyst Larry Biegelsen upgraded Johnson & Johnson to Outperform and raised his price target for the shares to $149 from $140. The healthcare giant closed Friday up 1c to $133.22. J&J is poised to reaccelerate its sales growth due to accretion from the Actelion acquisition, a "more measured" than expected impact from biosimilar competition, "solid performance" of key drugs and a pipeline that is "coming to fruition," Biegelsen tells investors in a research note. Further, the analyst believes Johnson & Johnson could continue to deliver margin improvement and faster earnings growth.
V Visa
$108.42

1.11 (1.03%)

10/10/17
WELS
10/10/17
UPGRADE
Target $120
WELS
Outperform
Visa upgraded to Outperform from Market Perform at Wells Fargo
Wells Fargo transferred coverage of Visa to Donald Fandetti who upgraded the stock to Outperform form Market Perform with a $120 price target. Fandetti believes Visa's earnings model for the networks remains very much intact and are supported by pricing power and significant capital return. He expects positive earnings revisions in 2018 and for Visa Europe integration to ultimately drive expense synergies as processing systems are consolidated.
09/29/17
09/29/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Regeneron (REGN) assumed with an Overweight at Piper Jaffray. 2. MasterCard (MA) and Visa (V) were initiated with an Overweight at Cantor Fitzgerald. 3. Liberty Global (LBTYA, LBTYK) and Liberty Global LiLAC (LILA) were initiated with a Buy at Buckingham. 4. Corbus Pharmaceuticals (CRBP) coverage assumed with a Buy at Noble Financial. 5. Medpace (MEDP) initiated with a Market Perform at Raymond James. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/02/17
BUCK
10/02/17
INITIATION
Target $129
BUCK
Buy
Visa initiated with a Buy at Buckingham
Buckingham analyst Chris Brendler started Visa with a Buy rating and $129 price target, saying he still views the payments networks as the stocks to own long-term in the increasingly attractive payments sector.
10/11/17
WELS
10/11/17
UPGRADE
Target $160
WELS
Outperform
MasterCard upgraded to Outperform from Market Perform at Wells Fargo
Wells Fargo analyst Donald Fandetti took over coverage of MasterCard (MA) with an Outperform rating and $160 price target, up from the firm's prior rating of Market Perform and $130 price target. Fandetti, who believes MasterCard is well positioned to deliver roughly 20% EPS growth, has a near-term preference for Visa (V), citing valuation and Visa Europe.
MA MasterCard
$146.42

0.77 (0.53%)

10/02/17
BUCK
10/02/17
INITIATION
Target $163
BUCK
Buy
MasterCard initiated with a Buy at Buckingham
Buckingham analyst Chris Brendler started MasterCard with a Buy rating and $163 price target, saying he still views the payments networks as the stocks to own long-term in the increasingly attractive payments sector.
09/28/17
CANT
09/28/17
INITIATION
Target $165
CANT
Overweight
MasterCard initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald initiated MasterCard with an Overweight rating and $165 price target.
CL Colgate-Palmolive
$74.68

1.78 (2.44%)

10/11/17
RHCO
10/11/17
UPGRADE
Target $85
RHCO
Buy
Colgate-Palmolive upgraded to Buy at SunTrust
As previously noted, SunTrust analyst William Chappell upgraded Colgate-Palmolive to Buy from Hold and raised his price target on the stock to $85 from $65. Chappell says the recent three consecutive quarters of weak results is an "anomaly" given the company's long term track record of consistent mid-single-digit or higher organic growth. The analyst also points to reacceleration in the emerging market middle class growth and favorable foreign exchange conditions for the first time in years.
10/11/17
RHCO
10/11/17
UPGRADE
RHCO
Buy
Colgate-Palmolive upgraded to Buy from Hold at SunTrust
09/25/17
MSCO
09/25/17
UPGRADE
MSCO
Overweight
Colgate-Palmolive upgraded to Overweight from Equal Weight at Morgan Stanley
09/25/17
09/25/17
UPGRADE
Target $84

Overweight
Colgate-Palmolive upgraded to Overweight at Morgan Stanley
As previously reported, Morgan Stanley analyst Dara Mohsenian upgraded Colgate-Palmolive to Overweight from Equal Weight and called the stock his top household products pick, saying he sees the company returning to above-peer growth beginning in Q4 and he thinks investors will soon "flock back" to emerging-market-centric names, like Colgate. The analyst, who thinks Colgate's valuation is attractive, also believes the company has multiple plausible strategic partners, unlike most peers. Mohsenian raised his price target on the stock to $84 from $75.
ABBV AbbVie
$91.91

0.74 (0.81%)

10/09/17
WBLR
10/09/17
NO CHANGE
Target $110
WBLR
Outperform
AbbVie fair value estimate raised to $110 from $76 at William Blair
William Blair analyst Y. Katherine Xu raised her fair value estimate for AbbVie to $110 to reflect progress with the pipeline and the recent Humira patent victory. The analyst now models Humira to maintain U.S. patent exclusivity through the end of 2022, extended from her previous estimate of 2020. Xu believes pivotal data readouts through year-end 2017 will continue to support the outperformance of AbbVie shares. She keeps an Outperform rating on the name.
10/02/17
10/02/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Akamai (AKAM) upgraded to Buy from Neutral at Guggenheim with analyst Robert Gutman citing valuation and raised its price target to $54 from $53. 2. Generac (GNRC) upgraded to Overweight from Sector Weight at KeyBanc with analyst Jeffrey Hammond saying the company is positioned to "meaningfully" re-accelerate growth and beat earnings expectations over the next 12-18 months. 3. Abercrombie & Fitch (ANF) upgraded to Hold from Sell at Argus with analysts John Eade and Annie Petrino saying new management is beginning to turn the operations around and shares have fallen to fallen for the past five years. 4. eGain (EGAN) upgraded to Buy from Hold at Craig-Hallum with analyst Jeff Van Rhee citing forward momentum building and compelling valuation. 5. AbbVie (ABBV) upgraded to Outperform from Market Perform at Leerink with analyst Geoffrey Porges saying he believes that there is still further upside as medium-and long-term estimates increase, and the company's multiple re-rates toward biopharmaceutical peers. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/11/17
COWN
10/11/17
UPGRADE
Target $105
COWN
Outperform
AbbVie upgraded to Outperform from Market Perform at Cowen
Cowen analyst Steve Scala upgraded AbbVie to Outperform and raised his price target for the shares to $105 from $95. AbbVie "showed the best" of all the companies at Cowen's Annual Therapeutics Conference last week, Scala tells investors in a research note. He increased his out-year estimates for AbbVie after several of its drugs were highlighted during the conference. The stock is attractively valued versus the group overall, Scala argues.
10/09/17
LEER
10/09/17
NO CHANGE
LEER
Leerink not worried about JAK safety, AbbVie '494 profile so far 'ok'
Leerink analyst Geoffrey Porges notes that the delayed approval of Incyte (INCY)/Eli Lilly (LLY) baricitinib and the reported thromboembolic events in AbbVie's (ABBV) ABT494/upadacitinib trials have called into question the safety of oral Janus kinase, or JAK, inhibitors. The analyst says that his detailed review of the safety literature suggests that these medicines offer an acceptable risk/benefit profile for serious inflammatory diseases and do not confer a significant increase in cardiovascular risk or venous thromboembolic events. Further, Porges continues to believe AbbVie's upadacitinib and Gilead's (GILD) filgotinib will be approved for serious inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease, and will capture the majority share of his peak risk-adjusted $12B estimated JAK market.
PYPL PayPal
$66.04

-0.19 (-0.29%)

10/06/17
BOFA
10/06/17
NO CHANGE
Target $78
BOFA
Buy
PayPal price target raised to $78 from $71 at BofA/Merrill
BofA/Merrill analyst Jason Kupferberg raised PayPal's Q3 revenue estimate to $3.203B from $3.181B, above the top end of guidance. His Q3 non-GAAP estimate is 44c, in line with consensus and the high end of guidance. Kupferberg continues to believe PayPal is the best positioned company under coverage to capitalize on the global mix shift of payments from offline to online/digital channels. The analyst reiterated his Buy rating ahead of the Q3 report on October 19 and increased his price target to $78 from $71 to reflect a modest increase in 2019 estimates.
10/11/17
10/11/17
UPGRADE
Target $76

Overweight
PayPal upgraded to Overweight on revised view of eBay risk at Morgan Stanley
As previously reported, Morgan Stanley analyst James Faucette upgraded PayPal (PYPL) to Overweight from Equal Weight, calling it among the few large companies that can deliver high-teens revenue and 20% EPS growth. While he previously was on the sidelines due to risk from its contract renegotiation with eBay (EBAY), he now believes the market may be overly concerned with it as he thinks the most likely renewal structure will feature rebates from PayPal to eBay, he tells investors. Faucette raised his price target on PayPal shares to $76 from $62. He also raised his price target on eBay to $33 from $29, though he keeps an Underweight rating on its shares.
10/11/17
MSCO
10/11/17
UPGRADE
MSCO
Overweight
PayPal upgraded to Overweight from Equal Weight at Morgan Stanley
10/10/17
FBCO
10/10/17
NO CHANGE
Target $70
FBCO
Outperform
PayPal price target raised to $70 from $63 at Credit Suisse
Credit Suisse analyst Paul Condra raised his price target for PayPal to $70 from $63 as he continues to like the stock primarily for its pure-play exposure to online/mobile commerce and the potential growth opportunities inherent to this industry. The analyst believes the market underestimates the stickiness of the PayPal platform and expects the brand could gain strength globally as its newly established tech/finance relationships deepen and evolve. He reiterates an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

19:15
10/20/17
10/20
19:15
10/20/17
19:15
General news
Breaking General news story  »

Federal Reserve Chair…

ATRS

Antares Pharma

$2.18

0.06 (2.83%)

18:59
10/20/17
10/20
18:59
10/20/17
18:59
Hot Stocks
FDA cannot approve Antares Pharma's Xyosted NDA »

Antares Pharma announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

18:55
10/20/17
10/20
18:55
10/20/17
18:55
Conference/Events
Federal Reserve Chairperson delivers a lecture at NEC Dinner »

Federal Reserve…

SHIP

Seanergy Marine

$1.24

0.0199 (1.63%)

17:50
10/20/17
10/20
17:50
10/20/17
17:50
Syndicate
Breaking Syndicate news story on Seanergy Marine »

Seanergy Marine files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HLI

Houlihan Lokey

$41.56

0.18 (0.43%)

17:49
10/20/17
10/20
17:49
10/20/17
17:49
Syndicate
Breaking Syndicate news story on Houlihan Lokey »

Houlihan Lokey files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

GEO

Geo Group

$26.20

0.2 (0.77%)

17:48
10/20/17
10/20
17:48
10/20/17
17:48
Syndicate
Breaking Syndicate news story on Geo Group »

Geo Group files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

, AIMT

Aimmune

$25.66

-0.06 (-0.23%)

17:37
10/20/17
10/20
17:37
10/20/17
17:37
Hot Stocks
DBV sinks following peanut allergy trial miss, Aimmune soars »

Shares of DBV…

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

AIMT

Aimmune

$25.66

-0.06 (-0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

KALV

KalVista

$11.26

1.99 (21.47%)

, DBVT

DBV Technologies

$48.07

0.92 (1.95%)

17:24
10/20/17
10/20
17:24
10/20/17
17:24
Hot Stocks
On The Fly: After Hours Movers »

HIGHER: KalVista (KALV),…

KALV

KalVista

$11.26

1.99 (21.47%)

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IPCI

Intellipharmaceutics

17:23
10/20/17
10/20
17:23
10/20/17
17:23
Hot Stocks
Breaking Hot Stocks news story on Intellipharmaceutics »

Armistice Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

17:21
10/20/17
10/20
17:21
10/20/17
17:21
Hot Stocks
DBV Technologies: PEPITES trial does not reach primary endpoint »

DBV Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WFC

Wells Fargo

$54.92

1.17 (2.18%)

17:08
10/20/17
10/20
17:08
10/20/17
17:08
Periodicals
Regulator criticizes Wells Fargo over deceptive auto insurance program, NYT says »

The Office of the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 02

    Nov

  • 07

    Nov

  • 29

    Nov

  • 15

    Jan

ALIM

Alimera Sciences

17:01
10/20/17
10/20
17:01
10/20/17
17:01
Syndicate
Alimera Sciences to sell $25M in shares in an 'at the market offering' »

On October 20, Alimera…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SYMC

Symantec

$32.66

0.33 (1.02%)

16:51
10/20/17
10/20
16:51
10/20/17
16:51
Syndicate
Breaking Syndicate news story on Symantec »

Symantec files to sell 1M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

EBMT

Eagle Bancorp

$19.55

0.15 (0.77%)

16:44
10/20/17
10/20
16:44
10/20/17
16:44
Hot Stocks
Breaking Hot Stocks news story on Eagle Bancorp »

EJF Capital reports 7%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KALV

KalVista

$11.26

1.99 (21.47%)

16:43
10/20/17
10/20
16:43
10/20/17
16:43
Hot Stocks
Breaking Hot Stocks news story on KalVista »

Longwood Fund II reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JAGX

Jaguar Health

$0.19

0.002 (1.08%)

16:41
10/20/17
10/20
16:41
10/20/17
16:41
Syndicate
Breaking Syndicate news story on Jaguar Health »

Jaguar Health files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$345.10

-6.71 (-1.91%)

16:40
10/20/17
10/20
16:40
10/20/17
16:40
Hot Stocks
Tesla amends 'warehouse agreements' to increase commitments to $1.1B »

On October 18,Tesla…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

  • 06

    Nov

SNV

Synovus

$47.30

0.54 (1.15%)

16:38
10/20/17
10/20
16:38
10/20/17
16:38
Hot Stocks
Synovus CBO sells 10,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Nov

  • 15

    Nov

GTXI

GTx

$7.92

0.1 (1.28%)

16:38
10/20/17
10/20
16:38
10/20/17
16:38
Syndicate
Breaking Syndicate news story on GTx »

GTx files to sell 8.77M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASB

Associated Banc-Corp

$25.90

1.3 (5.28%)

, BKMU

BankMutual

$10.80

0.55 (5.37%)

16:36
10/20/17
10/20
16:36
10/20/17
16:36
Conference/Events
BankMutual to host special shareholder meeting »

Special Shareholder…

ASB

Associated Banc-Corp

$25.90

1.3 (5.28%)

BKMU

BankMutual

$10.80

0.55 (5.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

CNXR

Connecture

$0.49

-0.01 (-2.00%)

16:35
10/20/17
10/20
16:35
10/20/17
16:35
Hot Stocks
Breaking Hot Stocks news story on Connecture »

Connecture trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$23.83

0.25 (1.06%)

, PG

Procter & Gamble

$88.25

-3.34 (-3.65%)

16:31
10/20/17
10/20
16:31
10/20/17
16:31
General news
On The Fly: Top stock stories for Friday »

Stocks opened sharply…

GE

General Electric

$23.83

0.25 (1.06%)

PG

Procter & Gamble

$88.25

-3.34 (-3.65%)

CELG

Celgene

$121.33

-14.63 (-10.76%)

SNCR

Synchronoss

$11.39

-0.12 (-1.04%)

IL

Bought by SNCR

SKX

Skechers

$33.99

9.96 (41.45%)

PYPL

PayPal

$70.97

3.72 (5.53%)

NCR

NCR Corp.

$33.05

-4 (-10.80%)

LHO

LaSalle Hotel

$28.52

-1.94 (-6.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 20

    Oct

  • 20

    Oct

  • 20

    Oct

  • 22

    Oct

  • 26

    Oct

  • 28

    Oct

  • 06

    Nov

  • 08

    Nov

  • 08

    Nov

  • 29

    Nov

  • 30

    Nov

16:30
10/20/17
10/20
16:30
10/20/17
16:30
Options
Preliminary option volume of 22.9M today »

Preliminary option volume…

MKL

Markel

$1,078.23

14.88 (1.40%)

, SNC

State National

$21.05

0.02 (0.10%)

16:26
10/20/17
10/20
16:26
10/20/17
16:26
Conference/Events
State National to host special shareholder meeting »

Special Shareholder…

MKL

Markel

$1,078.23

14.88 (1.40%)

SNC

State National

$21.05

0.02 (0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 26

    Oct

RYTM

Rhythm Pharmaceuticals

$23.08

-0.17 (-0.73%)

16:22
10/20/17
10/20
16:22
10/20/17
16:22
Hot Stocks
Breaking Hot Stocks news story on Rhythm Pharmaceuticals »

Orbimed Advisors reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.